Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Journal of Interprofessional Care|July 8, 2011
Development and validation of the interprofessional collaborator assessment rubric (ICAR)Vernon Curran, Ann Hollett, Lynn M Casimiro, et al.
Journal of Cutaneous Pathology|April 26, 2024
Subungual melanoma with cartilaginous differentiation: Molecular insightsUmayr Shaikh, Payal Shah, Victoria Jones, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 4, 2013
Relative bioavailability of tolvaptan administered via nasogastric tube and tolvaptan tablets swallowed intactElizabeth B McNeely, Jasmine A Talameh, Kirkwood F Adams, et al.
Cancer Chemotherapy and Pharmacology|May 20, 2017
Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairmentGhassan K Abou-Alfa, Lionel D Lewis, Patricia LoRusso, et al.
Cancer Research|August 23, 2014
AEG-1 promoter-mediated imaging of prostate cancerAkrita Bhatnagar, Yuchuan Wang, Ronnie C Mease, et al.
The Lancet. Oncology|February 26, 2018
Adjuvant vemurafenib in resected, BRAF<sup>V600</sup> mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichele Maio, Karl Lewis, Lev Demidov, et al.
Thoracic Cancer|September 14, 2022
MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLCLogan C Tyler, Anh T Le, Nan Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2026
Framework for statistical parametric mapping of the interactions between glioblastoma location, treatment, prognostic variables, and survival using a phase III trialFrancesco Sanvito, Catalina Raymond, Donatello Telesca, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2019
Health-related quality of life in patients with fully resected BRAF<sup>V600</sup> mutation-positive melanoma receiving adjuvant vemurafenibDirk Schadendorf, Anna Maria Di Giacomo, Lev Demidov, et al.
Molecular Oncology|March 26, 2022
Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinibRafal Dziadziuszko, Tiffany Hung, Kun Wang, et al.
Pageof 3